TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06137287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BOTOX
Description: Intramuscular Injection
Study: NCT05814536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-218 capsule
Description: Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
Study: NCT05573490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi- Qi Gong
Description: Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Games
Description: Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
Study: NCT06488209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAD191
Description: LAD191 SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo SC injection.
Study: NCT06128785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group
Description: Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal exhaust or until the fourth day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EA group
Description: Sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output.
Study: NCT05418894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Directional Deep Brain Stimulation
Description: Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
Study: NCT05425043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocytes
Description: Receive granulocytes for 7 consecutive days after engraftment post transplant
Study: NCT05025358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-118 tablet
Description: Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
Study: NCT06559384

Intervention type: OTHER
Intervention: Interviews
Description: semi-structured individual interviews

Intervention type: OTHER
Intervention: Interviews
Description: semi-structured individual interviews

Intervention type: OTHER
Intervention: Interviews
Description: semi-structured individual interviews
Study: NCT05373992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen Time Restriction (ST-Restricted)
Description: Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Description: Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen-time restricted plus aerobic exercise (STR+AE)
Description: Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Only
Description: Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
Study: NCT04911257

Intervention type: DEVICE
Intervention: Cervical or Lumbar Spinal fusion
Description: This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
Study: NCT05930834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
Study: NCT05160038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embodied virtual reality
Description: An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
Study: NCT06199947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies and Blood collection
Description: Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
Study: NCT06392685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silane coupling agent
Description: Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive containing silane.(Intervention 1 )
Description: Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acid resistance silane containing adhesive.(Intervention 2)
Description: Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
Study: NCT05716841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballistic exercises
Description: stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
Study: NCT06353659

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced Ultrasound
Description: Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced Ultrasound
Description: Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU
Study: NCT05042713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold, One Curve, OneFlare
Description: During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold, One Curve, OneFlare
Description: During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold, One Curve, OneFlare
Description: During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold, One Curve, OneFlare
Description: During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
Study: NCT04316221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eggs plus standard of care
Description: Eggs will be secured locally and delivered to families weekly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standar of care
Description: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
Study: NCT06643052

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05250687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR- High intensity focused ultrasound
Description: The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
Study: NCT06404060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Cardiopulmonary Rehabilitation
Description: Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
Study: NCT05326308

Intervention type: DRUG
Intervention: Zanubrutinib
Description: according to the Summary of Product Characteristics (SmPC).

Intervention type: DRUG
Intervention: Zanubrutinib
Description: according to the Summary of Product Characteristics (SmPC).

Intervention type: DRUG
Intervention: Zanubrutinib
Description: according to the Summary of Product Characteristics (SmPC).

Intervention type: DRUG
Intervention: Zanubrutinib
Description: according to the Summary of Product Characteristics (SmPC).

Intervention type: DRUG
Intervention: Obinutuzumab
Description: according to the Summary of Product Characteristics (SmPC).
Study: NCT05283382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Product
Description: Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a one-time dose of placebo capsules in the form of six capsules.
Study: NCT06554990

Intervention type: OTHER
Group type: OTHER
Intervention: physical therapy excersies
Description: 1- selected physical therapy exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory perceptual motor exercises
Description: selected sensory perceptual motor exercises
Study: NCT06332950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab, Irinotecan Liposome (II)
Description: Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab, Irinotecan Liposome (II), Famitinib
Description: Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib.
Study: NCT04921514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASRQ questionnaire
Description: During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCL-5 with LEC-5 questionnaire
Description: This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD.
Study: NCT05200936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120
Description: MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment which is designed to have no therapeutic value.
Study: NCT04804813

Intervention type: DRUG
Intervention: Cabozantinib
Description: Cabozantinib tablets
Study: NCT05427513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: will inject tranexamic acid in limb salvage surgery of sarcoma patient to check its efficacy in preventing blood loss

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline will be injected to ensure placebo
Study: NCT05559437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-bupivacaine 0.25
Description: The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-bupivacaine 0.25
Description: The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
Study: NCT05768516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of best practice for low back pain in primary care
Description: 1. Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~2. Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~3. Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~4. Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers.
Study: NCT05116020

Intervention type: OTHER
Intervention: Usual chiropractic care
Description: Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
Study: NCT06044181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser photocoagulation.
Description: If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
Study: NCT06043479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fever Management Education
Description: The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
Study: NCT05634954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH121224 (18F) Injection
Description: Single GEH121224 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH121224 (18F) Injection
Description: Single GEH121224 (18F) Injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT Scan
Description: Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT Scan
Description: Group 2: Static whole-body scans